Notes on Category Selection

Before selecting a category, please consider the following:

  • All studies of infants, children, or adolescents should be submitted to category (QHIV, SARS-CoV-2, or Both in Infants, Children, and Adolescents
  • All resistance studies and trials should be submitted to category (I) Resistance of HIV or SARS- CoV-2 to Small Molecules and Antibodies in Adults
  • All studies of Hepatitis (including A, B, C, and E in monoinfection or HIV coinfection) should be submitted to category (J) Hepatitis Viruses and Liver Complications in Adults, except that basic virology and pathogenesis of hepatitis tumor viruses should be submitted to category(C) HIV-Associated Tumor Viruses 
  • Diagnostics: Studies of new technologies related to HIV drug resistance, complications, tuberculosis, other opportunistic infections, hepatitis, or malignancies should be submitted to those specific categories. Studies applying new HIV diagnostics in populations should be submitted to category (THIV Testing in Adults: New Diagnostics, Population Studies, and Scale-Up
  • Population and Cost Modeling: Studies that include research on demography, population impact, modeling, and cost-effectiveness should be submitted to the relevant topical category. Reviewers of these abstracts will include individuals with modeling expertise
Basic Science
Category  Definition 
Virology of HIV or SARS-CoV-2 Studies of HIV or SARS-CoV-2 viral and host factors, including studies of replication in vitro, host restriction factors, viral life cycle, entry, tropism, and viral phenotypes
Pathogenesis of HIV or SARS-CoV-2: Human Studies and Animal Models Studies of factors influencing disease outcome in humans and animal models for HIV or SARS-CoV-2, including viral-host interactions, immune activation, host cell targets, cell compartments for infection, genotype (viral and host), and disease
HIV-Associated Tumor Viruses     Studies on basic science relating to HIV-associated tumor viruses (eg, Kaposi sarcoma-associated herpesvirus, Epstein-Barr virus, human papillomavirus, hepatitis B, Merkel cell polyomavirus) including viral life cycle, viral replication and transcription, viral-host interactions, pathogenesis and oncogenesis, and viral immunology
Host Immune Responses, Vaccines, and Immunotherapies: HIV or SARS-CoV-2 Studies of immune responses (B-cell, T-cell, and innate) to HIV and SARS-COV-2 infection and vaccines, and immunomodulatory therapeutic interventions (eg, cytokine interventions, passive antibody treatment)
HIV Reservoirs, Latency, and Curative Strategies Including Therapeutic Vaccines and Gene Therapy Studies of all aspects of HIV reservoirs, latency, and approaches to cure, including human and animal studies, related to these topics
Neuropathogenesis and Neurologic Complications of HIV, SARS-CoV-2, or Both in Adults

 

 

Studies of all aspects of HIV and SARS-CoV-2 neuropathogenesis including neuroimmunity, neurodegeneration, virology of central nervous system (CNS) infection, CNS complications of systemic infection (including neurocognitive dysfunction and associated factors or responses), cerebrovascular complications, and biomarkers (including neuroimaging)
Clinical
Clinical Pharmacology in Adults Studies of pharmacokinetics and pharmacodynamics (PK/PD) of small and large molecule drugs in animal models and adult humans, including drug absorption, distribution, metabolism, and excretion, novel dosing regimens, drug interactions, simulation and modeling, and novel or novel uses of objective adherence and exposure metrics. Studies of infants, children, or adolescents should be submitted to category (Q)
Antiviral Therapy: Pre-Clinical Data, Randomized Trials, Efficacy, and Effectiveness Studies in HIV or SARS-CoV-2 in Adults Studies of antiviral agents and combinations including monoclonal antibodies and new agents (all phases, including pre-clinical data, interventional trials, and observational and cohort studies) where the focus is on antiviral therapy and antiviral treatment strategies. Studies that focus on resistance should be submitted to category (I)
Resistance of HIV or SARS- CoV-2 to Small Molecules and Antibodies in Adults Studies of molecular mechanisms, pathogenesis, clinical implications, epidemiology, and diagnostics around resistance. Studies of infants, children, or adolescents should be submitted to category (Q)
Hepatitis Viruses and Liver Complications in Adults Studies of diagnostics, epidemiology, pathogenesis, and therapy for hepatitis viruses and liver complications of HIV or SARS-CoV-2 in adults. Studies of infants, children, or adolescents should be submitted to category (Q). Basic virology and pathogenesis of hepatitis tumor viruses should be submitted to (C)
AIDS-Related Malignancies Studies of the epidemiology, pathobiology, prognostic biomarkers, incidence, treatment, gynecologic malignancies, human papillomavirus screening, and prevention approaches for malignancies or premalignant lesions in patients with HIV infection
Cardiovascular Complications of HIV Infection and Antiretroviral Therapy Includes coronary, cardiac, and cerebrovascular complications, lipids, and peripheral vascular atheromatous disease
Other Complications of HIV Infection and Antiretroviral Therapy in Adults Studies of renal, bone, metabolic, and other complications (excluding neurologic or liver complications) in HIV. Neurologic complications should be submitted to category (F). Neuropathogenesis and CNS HIV Complications and liver complications should go to (J)  
Clinical Complications of COVID-19 Disease in Adults Studies of the natural history, clinical course, co-morbidities associated with, and complications of SARS CoV-2 infection in adults.  Includes “long hauler” studies and the courses of acute COVID-19 disease and any lingering complications. Studies of infants, children, or adolescents should be submitted to the respective category
Tuberculosis and Other Opportunistic Infections,

Including the Impact of HIV or SARS-CoV-2 in Adults

Basic and clinical studies of bacterial, fungal, parasitic, and non-hepatitis viral infections, including the impact of SARS-CoV-2 on tuberculosis and other opportunistic infections
Maternal and Fetal HIV or SARS-CoV-2: Transmission, Prevention, Treatment, Pregnancy, and Postpartum Maternal Health Studies of maternal-fetal transmission of HIV or SARS-CoV-2 (including mechanisms), approaches for prevention and treatment during pregnancy and breast feeding, possible risks associated with treatments in pregnancy and breastfeeding, postpartum maternal health, and early infant diagnosis
HIV, SARS-CoV-2, or Both in Infants, Children, and Adolescents Studies of the diagnosis, treatment, and management of HIV and related co-infections and co-morbidities, and of SARS-CoV-2 and multisystem inflammatory syndrome in children (MIS-C) in infants, children, and adolescents, including HIV-exposed uninfected children
Epidemiology/Public Health
Epidemiology of HIV in Adults Risk factors for acquisition or transmission of HIV, cohort studies, incidence and prevalence, morbidity and mortality, surveillance, transmission clusters, including phylogenetics, and molecular epidemiology
Epidemiology of COVID-19 Studies of the incidence and prevalence of SARS-CoV-2 infection around the world, including risk factors for community transmission and studies focused on vulnerable populations, including populations of color in the United States
HIV Testing in Adults: New Diagnostics, Population Studies, and Scale-Up Studies applying new HIV diagnostics in populations (eg, community-, partner-, and self-testing). Includes studies evaluating tests (such as incidence algorithms), new testing approaches, scale-up of HIV testing, and descriptive epidemiology of testing results
COVID-19 Testing: New Diagnostics for Virus and Antibodies; Testing in Various Populations; and Scale-Up Studies describing new diagnostics for testing for SARS-CoV-2 infection and antibodies, and evaluation of various testing approaches in populations. Use of SARS-CoV-2 testing for screening in specific populations (eg, school children, college students), scale-up of SARS-CoV-2 testing, and its cost-effectiveness
HIV Prevention Interventions in Adults Preclinical and clinical studies of microbicides, pre- and post-exposure prophylaxis, treatment as prevention, medical male circumcision, and other prevention interventions. Implementation of prevention strategies for HIV uninfected populations, and studies in which HIV incidence is the primary outcome. Studies of infants, children, and adolescents should be submitted to category (Q)
COVID-19 Prevention Interventions in Adults Studies of non-pharmacologic methods to prevent COVID-19, including facial masking, social distancing, hand hygiene, cohorting, environmental interventions, testing, and contact tracing, as well as pharmacologic methods for COVID-19 prevention (PrEP, PEP, antibodies)
Contraception, Sexually Transmitted Infections, and Reproductive Health in Adults Studies of the impact of contraceptive methods on HIV infection or disease; sexually transmitted infections; other aspects of sexual and reproductive health in HIV-infected or at-risk populations. Studies on HIV epidemiology, prevention, and treatment in women and in infants, children, and adolescents should be included in their respective categories
Implementation and Scale-Up of Prevention and Treatment for HIV and Impact of COVID-19 on HIV-Related Programs Including cascades of prevention and treatment, implementation science studies, experiences with scale-up of HIV prevention and treatment, and population-level impact of prevention and treatment on health outcomes of persons living with HIV and community health. Includes the impact of the COVID-19 pandemic on HIV risk, HIV testing, HIV prevention, and HIV treatment (including impacts on financing)